TY - JOUR
T1 - Biomarkers of response to advanced prostate cancer therapy
AU - Iacovelli, Roberto
AU - Ciccarese, Chiara
AU - Schinzari, Giovanni
AU - Rossi, Ernesto
AU - Maiorano, Brigida Anna
AU - Astore, Serena
AU - D’Angelo, Tatiana
AU - Cannella, Antonella
AU - Pirozzoli, Celeste
AU - Teberino, Maria Anna
AU - Pierconti, Francesco
AU - Martini, Maurizio
AU - Tortora, Giampaolo
N1 - Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Introduction: Prostate cancer (PCa) is one of the most common adult malignancies worldwide, and a major leading cause of cancer-related death in men in Western societies. In the last years, the prognosis of advanced PCa patients has been impressively improved thanks to the development of different therapeutic agents, including taxanes (docetaxel and cabazitaxel), second-generation anti-hormonal agents (abiraterone and enzalutamide), and the radiopharmaceutical Radium-223. However, great efforts are still needed to properly select the most appropriate treatment for each single patient. Areas covered: Several prognostic or predictive biomarkers have been studied, none of which has an established validated role in daily clinical practice. This paper analyzed the major biomarkers (including PSA, androgen receptor (AR) splice variants, βIII-tubulin, ALP, circulating tumor cells, and DNA repair genes) with a potential prognostic and/or predictive role in advanced PCa patients. Expert commentary: Surrogate biomarkers–measurable, reproducible, closely associated with tumor behavior and linked to relevant clinical outcomes–are urgently needed to improve PCa patient management.
AB - Introduction: Prostate cancer (PCa) is one of the most common adult malignancies worldwide, and a major leading cause of cancer-related death in men in Western societies. In the last years, the prognosis of advanced PCa patients has been impressively improved thanks to the development of different therapeutic agents, including taxanes (docetaxel and cabazitaxel), second-generation anti-hormonal agents (abiraterone and enzalutamide), and the radiopharmaceutical Radium-223. However, great efforts are still needed to properly select the most appropriate treatment for each single patient. Areas covered: Several prognostic or predictive biomarkers have been studied, none of which has an established validated role in daily clinical practice. This paper analyzed the major biomarkers (including PSA, androgen receptor (AR) splice variants, βIII-tubulin, ALP, circulating tumor cells, and DNA repair genes) with a potential prognostic and/or predictive role in advanced PCa patients. Expert commentary: Surrogate biomarkers–measurable, reproducible, closely associated with tumor behavior and linked to relevant clinical outcomes–are urgently needed to improve PCa patient management.
KW - AR-V7
KW - biomarker
KW - DRGs
KW - Prostate cancer
KW - PSA
UR - http://www.scopus.com/inward/record.url?scp=85078456624&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078456624&partnerID=8YFLogxK
U2 - 10.1080/14737159.2020.1707669
DO - 10.1080/14737159.2020.1707669
M3 - Review article
C2 - 31986925
AN - SCOPUS:85078456624
VL - 20
SP - 195
EP - 205
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 2
ER -